About Aspira Pathlab & Diagnostics Limited
Data last updated:
Aspira Pathlab & Diagnostics Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in diagnostic centers and pathology labs, a part of the broader healthcare sector. Incorporated on 03 July 1973, the company has been in operation for over 53 years.
Registered with ROC Mumbai under CIN L85100MH1973PLC289209. Listed on BSE: 540788.
Capital: an authorised share capital of ₹35 Cr and a paid-up capital of ₹15.79 Cr. Formerly known as Utkal Soap Products Ltd and Industrial Gas & Steel Products (India) Limited. It is led by directors including Manas Rajendra Mengar and Vaibhav Odhekar.
Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹24.98 Cr, a growth of 13.55% compared to the previous year. The net worth stands at ₹13.58 Cr (up 1.19% YoY). Total assets are valued at ₹16.27 Cr (up 1.88% YoY).
The company has a workforce of approximately 70 employees as per the latest available data.
The company is associated with 1 brand - Aspira Diagnostics. As per MCA filings, the company has satisfied charges of ₹6.22 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aspiradiagnostics.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Apps
- Registered AddressFlat No.2 R.D. Shah Bldg Shraddhanand Road Opp. Ghatkopar Railway Station Ghatkopa, R (West), Mumbai, Maharashtra, India – 400086
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics has undergone 3 name changes throughout its history. The company was previously known as Utkal Soap Products Ltd, Industrial Gas & Steel Products (India) Limited, and Utkal Soap Products Limited. The current legal name is Aspira Pathlab & Diagnostics Limited.
| Company Name | Status |
|---|---|
| Aspira Pathlab & Diagnostics Limited | Current |
| Utkal Soap Products Ltd | Previous |
| Industrial Gas & Steel Products (India) Limited | Previous |
| Utkal Soap Products Limited | Previous |
CIN History of Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L85100MH1973PLC289209, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85100MH1973PLC289209 | Current |
| L51909WB1973PLC028878 | Previous |
| L85100WB1973PLC028878 | Previous |
Associated Brands with Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics operates one associated brand: Aspira Diagnostics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pathology lab services are operated through a chain of facilities. | aspiradiagnostics.com |
Competitors & Alternatives of Aspira Pathlab & Diagnostics
Brands and companies operating in the same space as Aspira Pathlab & Diagnostics Limited include Dr Lal PathLabs, Redcliffe Labs, Metropolis India and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
 Dr Lal PathLabs | Chain of pathology and radiology labs | Gurugram, India, India | 1949 |
 Redcliffe Labs | Home-based diagnostic tests are booked via an online platform. | Noida, India, India | 2018 |
 Metropolis India | Diagnostic centers are operated as a nationwide chain. | Mumbai, India, India | 1981 |
 Orange health | At-home diagnostic tests are booked and collected by phlebotomists. | Bengaluru, India, India | 2020 |
 Agilus Diagnostics | Leading diagnostic chain providing quality blood test and full body checkup services | Gurugram, India, India | 1995 |
 Apollo Diagnostics | Provides pathology lab tests, health check packages, and home sample collection. | Hyderabad, India, India | 2015 |
 Sterling Accuris Diagnostics | Pathology diagnostic services are offered via a chain of labs. | Ahmedabad, India, India | 2015 |
 Airmed | Provider of a chain of diagnostic labs | Ahmedabad, India, India | 2016 |
Business Activity of Aspira Pathlab & Diagnostics
The main business activity of Aspira Pathlab & Diagnostics is hospital and medical care. In detail, this covers medical and dental practice, nursing, pathology, blood bank services, etc..
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q2 | Medical and dental practice, Nursing, pathology, blood bank services, etc. | Locked |
Business activity turnover details for Aspira Pathlab & Diagnostics Limited
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics Limited is audited by P Khetan & Co. for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P Khetan & Co. | Locked | Locked | Locked |
Complete auditor history for Aspira Pathlab & Diagnostics Limited
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Aspira Pathlab & Diagnostics Limited
Aspira Pathlab & Diagnostics has 7 current directors and 25 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manas Rajendra Mengar | Director | 12 Aug 2023 | 3 Years 1 Months | Current |
| Vaibhav Odhekar Also directs: Omizoo Private Limited, Jivi Care Private Limited | Additional Director | 23 May 2026 | 0 Years 4 Months | Current |
| Kiran Raghavendra Awasthi Also directs: Raj Oil Mills Limited | Director | 12 Nov 2025 | 0 Years 10 Months | Current |
| Nikunj Velji Mange Also directs: Growfresh Agro Venture LLP, Ybl Properties LLP | Director | 29 Aug 2020 | 6 Years 1 Months | Current |
| Haseeb Ahmad Drabu Also directs: Essar Power Limited, Essar Ports & Logistics Limited, Salaya Bulk Terminals Limited and 5 more | Director | 27 Oct 2018 | 7 Years 11 Months | Current |
| Pankaj Jashwant Shah Also directs: Aspira Dna Diagnostics Gujarat LLP | Managing Director | 01 Aug 2016 | 10 Years 2 Months | Current |
Financials of Aspira Pathlab & Diagnostics Limited FY 2025-26 filings available
Aspira Pathlab & Diagnostics Limited reported revenue of ₹24.98 Cr (up 13.55% YoY) for FY 2025-26.
Financial Highlights
FY 2024-25 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Income statement | ||
| Revenue | 22.00 | 13.20 |
| Revenue growth | +28.7% | +9997.0% |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Profit before tax | 2.02 | (2.69) |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Balance sheet | ||
| Total assets | 15.92 | 13.34 |
| Net worth | 13.37 | 11.22 |
| Total debt | 1.99 | 1.70 |
| Cash & bank | 2.14 | 1.38 |
| Net working capital | 3.81 | 2.98 |
| Cash flow | ||
| Cash from operations | 1.83 | 1.05 |
| Cash from investing | 0.12 | 0.14 |
| Cash from financing | (0.99) | (0.95) |
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | +9997.0% | +9997.0% | +78.5% | +9997.0% | +9997.0% |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +27.3% | +28.3% | +12.0% | -2.4% | +12.7% | +13.9% | -5.7% |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Balance sheet | |||||||
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Net worth | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Cash & bank | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Cash flow | |||||||
| Cash from operations | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Cash from investing | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Cash from financing | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 | 6.18 |
| Revenue growth (YoY) | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | +51.3% | +56.4% | +86.1% |
| Other income | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 | 0.08 |
| Total expenses | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 | 4.82 |
| EBITDA | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 | 1.36 |
| EBITDA margin | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% | +22.0% |
| Depreciation | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 | 0.36 |
| Interest | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.08 |
| Profit before tax | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 | 1.00 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Jun 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.25 | 5.78 | 5.41 | 6.18 | 4.64 | 3.82 | 2.60 |
| Revenue growth (YoY) | +13.2% | +51.3% | +9997.0% | +9997.0% | +78.5% | +9997.0% | +9997.0% |
| Other income | 0.11 | 0.13 | 0.09 | 0.08 | 0.16 | 0.08 | 0.10 |
| EBITDA | 0.68 | 0.92 | 0.61 | 1.28 | 0.27 | (0.20) | (0.43) |
| EBITDA margin | +13.0% | +15.9% | +11.3% | +20.7% | +5.8% | -5.2% | -16.5% |
| Depreciation | 0.37 | 0.37 | 0.39 | 0.36 | 0.38 | 0.38 | 0.39 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.42 | 0.68 | 0.31 | 1.00 | 0.05 | (0.50) | (0.72) |
| EPS (₹) | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | (0.49) | (0.70) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Revenue | 22.00 | 13.20 |
| Revenue growth | +28.7% | +9997.0% |
| Other income | 0.39 | 0.42 |
| Total expenses | 18.53 | 14.40 |
| Employee cost | 7.33 | 6.20 |
| EBITDA | 3.47 | (1.20) |
| EBITDA margin | +15.8% | -9.1% |
| Depreciation | 1.49 | 1.54 |
| Interest | 0.35 | 0.37 |
| Profit before tax | 2.02 | (2.69) |
| Tax | 0.00 | 0.00 |
| Net profit | 2.05 | (2.69) |
| Net profit margin | +9.3% | -20.4% |
| EPS (₹) | 1.97 | (2.60) |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 16.43 | 16.30 |
| Reserves & surplus | (3.06) | (5.08) |
| Shareholders' funds (net worth) | 13.37 | 11.22 |
| Minority interest | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 |
| Unsecured loans | 1.99 | 1.70 |
| Total debt | 1.99 | 1.70 |
| Total liabilities | 15.92 | 13.34 |
| Assets | ||
| Gross block | 18.31 | 17.20 |
| Net block | 6.53 | 6.79 |
| Capital work in progress | 0.00 | 0.00 |
| Investments | 0.08 | 0.00 |
| Inventories | 0.51 | 0.45 |
| Sundry debtors | 2.35 | 2.24 |
| Cash & bank balances | 2.14 | 1.38 |
| Loans & advances | 0.36 | 0.28 |
| Total current assets | 5.36 | 4.35 |
| Total current liabilities | 1.55 | 1.37 |
| Net working capital | 3.81 | 2.98 |
| Total assets | 15.92 | 13.34 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Opening cash | 0.80 | 0.57 |
| Net cash from operating activities | 1.83 | 1.05 |
| Net cash from investing activities | 0.12 | 0.14 |
| Net cash from financing activities | (0.99) | (0.95) |
| Net change in cash | 0.95 | 0.24 |
| Closing cash | 2.14 | 1.38 |
| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Growth | ||
| Sales growth | +66.7% | +9997.0% |
| EBITDA growth | +9998.0% | +9997.0% |
| PBT growth | +9998.0% | +9997.0% |
| Net income growth | +9998.0% | +9997.0% |
| Profitability & leverage | ||
| Net income margin | +9.2% | -20.4% |
| Return on capital employed | +11.5% | 0.0% |
| Return on net worth | +16.5% | 0.0% |
| Debt / equity | 0.15 | 0.15 |
| Long-term debt / equity | 0.09 | 0.09 |
| Interest cover | 17.68 | -13.50 |
| Efficiency & per share | ||
| Fixed asset turnover | 1.24 | 0.77 |
| Inventory turnover | 45.83 | 29.33 |
| Debtors turnover | 9.59 | 5.89 |
| EPS (₹) | 1.97 | (2.60) |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 7.03 | 5.07 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.17 | 6.52 | 5.12 | 8.09 | 5.25 | 5.78 | 5.41 | 6.18 |
| Revenue growth (YoY) | +17.5% | +12.8% | -5.4% | +30.9% | +13.2% | +51.3% | +56.4% | +86.1% |
| Other income | 0.12 | 0.14 | 0.13 | 0.14 | 0.11 | 0.13 | 0.09 | 0.08 |
| Total expenses | 5.83 | 6.86 | 6.33 | 5.90 | 4.43 | 4.72 | 4.64 | 4.82 |
| EBITDA | 0.34 | (0.34) | (1.21) | 2.19 | 0.82 | 1.06 | 0.77 | 1.36 |
| EBITDA margin | +5.5% | -5.2% | -23.6% | +27.1% | +15.6% | +18.3% | +14.2% | +22.0% |
| Depreciation | 0.41 | 0.40 | 0.38 | 0.40 | 0.37 | 0.37 | 0.39 | 0.36 |
| Interest | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.08 |
| Profit before tax | (0.04) | (0.70) | (1.56) | 1.83 | 0.47 | 0.73 | 0.38 | 1.00 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.98 | 22.00 | 13.20 | 14.46 | 19.54 | 15.21 | 8.42 |
| Revenue growth | +27.3% | +28.3% | +12.0% | -2.4% | +12.7% | +13.9% | -5.7% |
| Other income | 0.52 | 0.39 | 0.42 | 0.32 | 0.09 | 0.20 | 0.29 |
| Total expenses | 23.52 | 18.48 | 14.40 | 12.86 | 13.17 | 11.69 | 10.26 |
| Employee cost | 0.00 | 7.33 | 6.20 | 5.59 | 5.02 | 4.03 | 4.95 |
| EBITDA | 1.46 | 3.52 | (1.20) | 1.60 | 6.37 | 3.52 | (1.84) |
| EBITDA margin | +5.8% | +16.0% | -9.1% | +11.1% | +32.6% | +23.1% | -21.9% |
| Depreciation | 1.54 | 1.49 | 1.54 | 1.59 | 1.64 | 1.44 | 1.66 |
| Interest | 0.39 | 0.35 | 0.37 | 0.42 | 0.37 | 0.89 | 1.01 |
| Profit before tax | 0.05 | 2.07 | (2.69) | (0.09) | 4.45 | 1.39 | (4.22) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Net profit | 0.05 | 2.10 | (2.69) | (0.09) | 4.45 | 1.39 | (4.25) |
| Net profit margin | +0.2% | +9.6% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.57 | 16.43 | 16.30 | 16.18 | 16.08 | 15.99 | 14.91 |
| Reserves & surplus | (2.99) | (3.01) | (5.08) | (2.47) | (2.43) | (6.91) | (10.42) |
| Shareholders' funds (net worth) | 13.58 | 13.42 | 11.22 | 13.71 | 13.65 | 9.08 | 4.49 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 4.91 |
| Unsecured loans | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 0.83 | 3.28 |
| Total debt | 1.97 | 1.99 | 1.70 | 2.35 | 3.06 | 1.31 | 8.19 |
| Total liabilities | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Assets | |||||||
| Gross block | 20.54 | 18.31 | 17.20 | 16.88 | 16.87 | 13.41 | 12.91 |
| Net block | 7.21 | 6.53 | 6.79 | 8.00 | 9.58 | 7.75 | 8.70 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.70 | 0.51 | 0.45 | 0.40 | 0.40 | 0.37 | 0.28 |
| Sundry debtors | 1.73 | 2.35 | 2.24 | 2.34 | 4.49 | 1.70 | 0.60 |
| Cash & bank balances | 1.68 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Loans & advances | 0.47 | 0.36 | 0.28 | 0.77 | 0.60 | 0.62 | 1.31 |
| Total current assets | 4.58 | 5.36 | 4.35 | 5.86 | 7.13 | 3.88 | 3.29 |
| Total current liabilities | 2.23 | 1.55 | 1.37 | 0.91 | 1.14 | 1.18 | 1.44 |
| Net working capital | 2.35 | 3.81 | 2.98 | 4.95 | 5.99 | 2.70 | 1.85 |
| Total assets | 16.27 | 15.97 | 13.34 | 16.43 | 16.99 | 10.60 | 12.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.75 | 0.80 | 0.57 | 1.35 | 1.19 | (2.22) | (1.87) |
| Net cash from operating activities | 1.45 | 1.88 | 1.05 | (0.01) | 2.03 | 5.67 | (1.87) |
| Net cash from investing activities | (0.80) | 0.07 | 0.14 | 0.16 | (0.51) | (0.09) | 0.24 |
| Net cash from financing activities | (1.14) | (0.99) | (0.95) | (0.94) | (1.35) | (2.17) | 1.27 |
| Net change in cash | (0.49) | 0.95 | 0.24 | (0.79) | 0.17 | 3.41 | (0.35) |
| Closing cash | 1.26 | 2.14 | 1.38 | 2.35 | 1.64 | 1.19 | 1.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +13.6% | +66.7% | -8.7% | -26.0% | +28.5% | +80.6% | +10.2% |
| EBITDA growth | -58.5% | +9998.0% | - | -74.9% | +81.0% | +9998.0% | +43.2% |
| PBT growth | -97.6% | +9998.0% | -2888.9% | - | +220.1% | +9998.0% | +18.5% |
| Net income growth | -97.6% | +9998.0% | -2888.9% | - | +220.1% | +9998.0% | +18.0% |
| Revenue CAGR (3Y) | +20.0% | +4.0% | -4.6% | +19.8% | +36.8% | +51.7% | +122.9% |
| EBITDA CAGR (3Y) | -3.0% | -17.9% | - | - | - | - | -10.5% |
| Profitability & leverage | |||||||
| Net income margin | +0.2% | +9.4% | -20.4% | -0.6% | +22.8% | +9.1% | -50.5% |
| Return on capital employed | - | +11.7% | 0.0% | 0.0% | +17.6% | +11.5% | 0.0% |
| Return on net worth | - | +16.9% | 0.0% | 0.0% | +23.1% | +15.2% | 0.0% |
| Debt / equity | - | 0.15 | 0.16 | 0.20 | 0.19 | 0.70 | 1.47 |
| Long-term debt / equity | - | 0.09 | 0.11 | 0.15 | 0.13 | 0.37 | 0.84 |
| Interest cover | -487.50 | 17.24 | -13.50 | 4,200.00 | 7.82 | 42.79 | -28.86 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.24 | 0.77 | 0.86 | 1.29 | 1.16 | 0.69 |
| Inventory turnover | - | 45.83 | 31.06 | 36.15 | 50.75 | 46.80 | 30.07 |
| Debtors turnover | - | 9.59 | 5.76 | 4.23 | 6.31 | 13.23 | 12.03 |
| EPS (₹) | 0.05 | 2.01 | (2.60) | (0.09) | 4.33 | 1.34 | (4.56) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.08 | 5.07 | 7.60 | 7.64 | 3.29 | (1.21) |
Shareholding Pattern of Aspira Pathlab & Diagnostics Limited
Shareholding for the quarter ended Mar 2026: promoters hold 18.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 81.60%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 18.40% | 18.40% | 18.40% | 18.40% |
| Public | 81.60% | 81.60% | 81.60% | 81.60% |
Charges & Borrowings of Aspira Pathlab & Diagnostics
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Jul 2020 | Hdfc Bank Limited | ₹96.8 Lakh | Satisfied |
| 04 Jun 2018 | Hdfc Bank Limited | ₹50 Lakh | Satisfied |
| 07 Dec 2016 | Hdfc Bank Limited | ₹4.75 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics Limited has a workforce of 70 employees as of Dec 20, 2024.
Employee and EPFO history for Aspira Pathlab & Diagnostics Limited
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Aspira Pathlab & Diagnostics
GST registrations and filing compliance for Aspira Pathlab & Diagnostics Limited
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Aspira Pathlab & Diagnostics
Credit ratings, litigation, and regulatory alerts for Aspira Pathlab & Diagnostics Limited
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Aspira Pathlab & Diagnostics
MSME payment history for Aspira Pathlab & Diagnostics Limited
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Aspira Pathlab & Diagnostics
Corporate group structure for Aspira Pathlab & Diagnostics Limited
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Aspira Pathlab & Diagnostics
MCA filings and documents for Aspira Pathlab & Diagnostics Limited
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Aspira Pathlab & Diagnostics
Recent News on Aspira Pathlab & Diagnostics
Frequently Asked Questions about Aspira Pathlab & Diagnostics Limited
Aspira Pathlab & Diagnostics is an active public limited company in the healthcare sector based in Mumbai, Maharashtra, India. It was incorporated on 03 July 1973 (53+ years old) and is registered under CIN L85100MH1973PLC289209. Listed on BSE: 540788. The company has 70 employees.
Aspira Pathlab & Diagnostics reported revenue of ₹24.98 Cr for FY 2025-26 (up 13.55% YoY) based on standalone financials.
The current directors of Aspira Pathlab & Diagnostics are:
- Manas Rajendra Mengar - Director
- Vaibhav Odhekar - Additional Director
- Kiran Raghavendra Awasthi - Director
- Nikunj Velji Mange - Director
- Haseeb Ahmad Drabu - Director
- Pankaj Jashwant Shah - Managing Director
- Avinash Chander Mahajan - Director
The primary industry of Aspira Pathlab & Diagnostics is healthcare. The company specifically operates in diagnostic centers and pathology labs. The company is currently active in this sector.
Yes. Aspira Pathlab & Diagnostics is listed on BSE with code 540788.
Aspira Pathlab & Diagnostics can be reached at the registered office: Flat No.2 R.D. Shah Bldg Shraddhanand Road Opp. Ghatkopar Railway Station Ghatkopa, R West, Mumbai, Maharashtra, India – 400086, or through the website aspiradiagnostics.com.